Exxel Pharma (“Exxel” or “The Company”) is a development stage company that combines world-class leadership, expert technological know-how and experience from the pharmaceutical industry to develop medicines for significant unmet medical needs.
The Company is focused on the development of small-molecule therapeutics for safe, non-addictive treatment of a pain, PTSD and substance (e.g. opioid) use disorders. Exxel is specifically targeting disease areas with significant unmet medical needs and aims to become the leader in therapeutics that enhance endocannabinoid signalling by FAAH inhibition.
Exxel Pharma’s pipeline counts two functionally distinct FAAH inhibitors, URB937 and the URB597-based ARN molecules. URB937 is peripherally restricted (i.e., is inactive in the brain and spinal cord), whereas the ARN molecules are global active FAAH inhibitors. The therapeutics were developed at the University of California, Irvine by our Chief Scientific Officer, Professor Daniele Piomelli, and are protected by multiple issued and pending patents. URB937 is positioned as a safe, non-addictive alternative to opiate and non-steroidal anti-inflammatory pain management drugs, and the lead indication is peripheral neuropathic pain. The URB597-based ARN molecules are being developed for treatment of PTSD and other diseases of the CNS.